Abstract
Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have